Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL378762 | 0.80 | — | — | |
| SCHEMBL4600069 | 0.75 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL9295399 | 0.75 | ALDH1A1 (0.34) | TSHRTDP1ALDH1A1 | |
| SCHEMBL9936989 | 0.75 | ALDH1A1 (0.30) | TSHRTDP1ALDH1A1 | |
| SCHEMBL15286495 | 0.75 | POLB (0.32) | — | |
| SCHEMBL15288773 | 0.75 | — | — | |
| SCHEMBL4279071 | 0.71 | CASP6 (0.34) | TSHRTDP1ALDH1A1 | |
| SCHEMBL4272720 | 0.71 | VCAM1 (0.33) | — | |
| SCHEMBL8811802 | 0.69 | — | — | |
| SCHEMBL10957830 | 0.67 | ALDH1A1 (0.33) | TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2751098-B1 | AN IMPROVED PROCESS FOR PREPARATION OF ZOLMITRIPTAN | EMCURE PHARMACEUTICALS LTD (IN) | 2017-11-29 | — | — | EP | disclosed |
| US-9006453-B2 | Process for preparation of zolmitriptan | EMCURE PHARMACEUTICALS LIMITED (IN) | 2015-04-14 | — | — | US | disclosed |
| EP-2830434-A1 | USE OF PARA NITRO AMINO DERIVATIVES IN FEED FOR REDUCING ME-THANE EMISSION IN RUMINANTS | DSM IP Assets B.V. (NL) | 2015-02-04 | — | — | EP | disclosed |
| US-20140228582-A1 | PROCESS FOR PREPARATION OF ZOLMITRIPTAN | EMCURE PHARMACEUTICALS LIMITED (IN) | 2014-08-14 | — | — | US | disclosed |
| EP-2751098-A2 | AN IMPROVED PROCESS FOR PREPARATION OF ZOLMITRIPTAN | Emcure Pharmaceuticals Limited (IN) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013144786-A1 | USE OF PARA NITRO AMINO DERIVATIVES IN FEED FOR REDUCING ME-THANE EMISSION IN RUMINANTS | DSM IP ASSETS B.V. (NL) | 2013-10-03 | — | — | WO | disclosed |
| CN-101743246-B | 2-oxo-2- (2-phenyl-5,6,7,8-tetrahydro-indolizin-3-yl) -acetamide derivatives and related compounds as antifungal agents | F2G LTD | 2013-07-17 | — | — | CN | disclosed |
| WO-2013057739-A2 | AN IMPROVED PROCESS FOR PREPARATION OF ZOLMITRIPTAN | EMCURE PHARMACEUTICALS LIMITED (IN) | 2013-04-25 | — | — | WO | disclosed |
| CN-101743246-A | 2-oxo-2- (2-phenyl-5,6,7,8-tetrahydro-indolizin-3-yl) -acetamide derivatives and related compounds as antifungal agents | F2G LTD | 2010-06-16 | — | — | CN | disclosed |
| WO-2004063175-A1 | A NOVEL AND AN IMPROVED PROCESS FOR THE PREPARATION OF (S)-4-(4-AMINOBENZYL)-2- OXAZOLIDINONE | NATCO PHARMA LIMITED (IN) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228582-A1 | PROCESS FOR PREPARATION OF ZOLMITRIPTAN | HRH2, HTR1D, TMEM97 | ACHE 1411/4885HSD17B10 1527/4885TSHR 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.